Jonathan Kell

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

Alan K. Burnett, Robert K. Hills, Donald Milligan et al. · Journal of Clinical Oncology · 2010 · 652 citations · Full text

Medicine, Oncology, Pharmacology +17

Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial

Alan K. Burnett, Nigel H. Russell, Robert K. Hills et al. · The Lancet Oncology · 2015 · 543 citations

Medicine, Hematology, Oncology +8

Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia

Alan K. Burnett, Nigel H. Russell, Robert K. Hills et al. · Journal of Clinical Oncology · 2012 · 408 citations · Full text

Medicine, Oncology, Pharmacology +16

A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients

Alan K. Burnett, Nigel H. Russell, Robert K. Hills et al. · Blood · 2015 · 295 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +5

Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): An overview from the research on adverse drug events and reports (RADAR) project

June M. McKoy, Cara Angelotta, Charles L. Bennett et al. · Leukemia Research · 2006 · 179 citations

Pharmacy, Pharmacology, Pharmacotherapy +12